United States Department of Justice

The United States Department of Justice enters the account most visibly through its prosecution of Purdue Pharma over OxyContin: a federal case that reached from a small Virginia prosecutors’ office to the department’s headquarters, survived pressure over its timing and scope, and ended in guilty pleas and substantial fines. Its significance lies both in making a pharmaceutical company answer criminally for its marketing and in revealing the uneven boundaries of enforcement: corporate misconduct could be framed as a federal crime, while people who used or sold drugs were often dealt with through a punitive system the book questions.

The Federal Case in Southwest Virginia

The investigation was led by prosecutors in Abingdon, including John Brownlee, with Randy Ramseyer and Rick Mountcastle among the prosecutors whose work shaped the case. Their office was small, but it had experience pursuing medical professionals who overprescribed controlled drugs. Since OxyContin’s introduction, the prosecutors had successfully brought cases against ten doctors, pharmacists, and dentists, including professionals who prescribed to children as young as nine. One doctor had issued prescriptions from the back seat of his car. The emerging OxyContin case grew out of this local prosecutorial work rather than an abstract national inquiry.

Over five years, nine state and federal agencies helped assemble the investigation. The legal route was narrower than the human consequences surrounding it. Prosecutors did not have to prove that Purdue’s conduct directly caused particular overdoses, addictions, or cases of misuse. They had to establish that the company had criminally misbranded its drug: a technical offense that could encompass fraudulent promotion or marketing a drug for an unapproved use. That distinction enabled the government to pursue a case even where proving a direct causal chain from corporate promotion to individual harm would have been difficult.

The book presents the case against a backdrop of earlier efforts that had often failed. A few federal prosecutors had challenged Purdue’s promotion, with some success, but one earlier U.S. attorney who pressed the company to end doctor junkets and drop its 160-milligram pill later became a consultant for Purdue Pharma. Against that history, the Abingdon team’s years of work represented a sustained attempt to hold the company to account through criminal law.

Charges, Negotiations, and Pressure

By the fall of 2006, prosecutors believed the evidence could support felony charges extending beyond misbranding to mail fraud, wire fraud, and money laundering, including charges against the company and its senior executives. A memorandum to Brownlee reflected the possibility of a broader indictment. The case was subsequently narrowed as it moved through the United States Department of Justice, while Purdue’s lawyers, including Rudy Giuliani, lobbied against felony charges for the executives. The amount of the proposed fines also shifted sharply: Purdue initially offered $10 million, while the government’s initial proposal was $1 billion.

Pressure on the investigation had surfaced before the final negotiations. In 2005, Purdue’s lawyers raised concerns about Brownlee’s investigative tactics with then–deputy attorney general James Comey. Comey relayed those concerns, and Brownlee drove to Washington to explain his strategy. Comey told him to return to Virginia and continue the case. The episode showed that the investigation was not insulated from senior-level attention, but Brownlee was able to maintain it at that point.

The final deadline brought another intervention. In October 2006, on the night before the plea agreement was set to expire, a senior Justice Department officer called Brownlee at home at the request of a Purdue lawyer and urged him to grant the company more time. Brownlee declined to extend the process. Purdue accepted the agreement that night rather than risk more serious charges or a trial in western Virginia, where OxyContin’s effects were well known. Eight days later, Brownlee was surprised to see his name on a list of five U.S. attorneys slated for dismissal. He was not ultimately fired, but the episode added to criticism of then–attorney general Alberto Gonzales and allegations that U.S. attorneys’ work had been subject to improper influence. The account does not present the listing as proof that Brownlee was dismissed for the Purdue case; it shows how the timing intensified scrutiny of the department’s independence.

The 2007 Settlement

In May 2007, Brownlee announced the outcome at an office building in downtown Roanoke. Purdue would pay $600 million to resolve federal criminal and civil misbranding charges. Purdue Frederick Company, Inc., a Purdue-owned holding company, pleaded guilty to one felony count of misbranding. The company admitted that, over six years, it had fraudulently marketed OxyContin as less prone to abuse and less likely to produce narcotic side effects than immediate-release versions of the drug.

Three senior executives—Paul Goldenheim, Michael Friedman, and Howard Udell—pleaded guilty to misdemeanor misbranding. Their $34.5 million in penalties was paid by the firm on their behalf. The executives did not stipulate that they had direct knowledge of the misbranding; the plea language instead allowed the court to accept the stated facts in support of their guilty pleas. The distinction illustrates both the reach and the limits of the settlement: senior leaders faced criminal convictions, but the agreement did not establish their direct knowledge in the terms prosecutors had initially contemplated.

The fines against the company and executives amounted to about 90 percent of Purdue’s profits from OxyContin’s launch in 1996 through 2001, the year the company dropped language about the timed-release mechanism’s ability to reduce abuse liability. The penalty was described as the eleventh-largest fine paid by a pharmaceutical firm in the department’s history. It was a substantial financial and legal consequence, but the plea agreement did not require the executives to serve jail time. A sentencing hearing in Abingdon was planned for July, where grieving parents would be able to describe the drug’s effects on the record; the judge would determine the exact terms of probation and community service.

Enforcement and Unequal Consequences

The case’s achievement is set against a broader question about what the justice system chooses to prosecute. In the book’s account, the United States Department of Justice pursued Purdue for misleading promotion, while many people caught in the opioid crisis encountered arrest and imprisonment for drug-related conduct. Ronnie Jones’s case makes that contrast stark: he was serving his third prison term for heroin distribution, and the narrative notes that three-quarters of federal drug offenders were Black or Hispanic, while people of color made up 57 percent of state-imprisoned drug offenders. Those statistics are presented as evidence of unequal enforcement, not as a claim that the Purdue case itself caused those disparities.

The same section questions a public-health refrain that arrests alone cannot end the crisis when it appears to apply more readily to white opioid users than to Black and brown people imprisoned for selling drugs. It contrasts incarceration with approaches that link people to treatment, housing, case management, and employment. The Equal Justice Initiative, led by Bryan Stevenson, is described as sending clients to cities where such supports and harm-reduction measures are more available and where some addicted low-level offenders can be diverted before prosecution. That example is not a United States Department of Justice program; it clarifies the book’s larger distinction between punishment and support.

The department’s role is therefore neither simply vindicated nor dismissed. Its prosecution demonstrated that federal law could reach a company’s promotion of a powerful medication, even without proving that the conduct caused each individual harm. Yet the negotiated pleas, the absence of jail time for the executives, and the contrast with drug-related imprisonment leave open a question of proportionality. The case becomes one measure of federal accountability—and, beside the wider criminal-justice system, a reminder that accountability was applied differently to corporate decision-makers and people at the street level.